Pfizer pleads guilty, but drug sales continue to soarBMJ 2004; 328 doi: http://dx.doi.org/10.1136/bmj.328.7450.1217 (Published 20 May 2004) Cite this as: BMJ 2004;328:1217
- Jeanne Lenzer
- New York
Pfizer, the world's largest drug maker, pleaded guilty on 13 May to numerous civil and criminal charges for illegally promoting the off-label use of gabapentin (Neurontin). It has agreed to pay a $240m (£136m; €200m) criminal fine and $152m to state and federal healthcare programmes. The fine is the second largest given in the industry.
Meanwhile, off-label sales of gabapentin continue to soar, despite evidence that the drug is not effective for some of the problems it is used to treat.
David Franklin, 42, a microbiologist and former Harvard …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial